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2Abstract:
Oral squamous cell carcinoma is the most common intraoral malignancy. Our unit has
advocated radical primary surgery with adjuvant treatment where indicated. The main aims of
this work are to identify the overall survival of a consecutive series of patients and to relate
survival to clinical and pathological factors.
Methods
Kaplan-Meier curves were produced for site, gender, TNM status, and post-operative
radiotherapy. Statistical significance was set at p<0.05. The data were analysed using the
software IBM SPSS Statistics version 23.
Results
A total of 921 patients were recorded in the database with a diagnosis of oral squamous cell
carcinoma out of a total of 1958 (43.1%). The earliest date of diagnosis was 1973. The data
were censored at 31 March 2016. The database comprised 340 women (36.92%) and 581 men
(63.08%). A total of 339 deaths were recorded (34.51%): 117 women (33.7%) and 222 men
(65.49%). The mean age at death was 73.37 years (range: 31.38 to 97.51 years) and 68.65
years (range: 33.29 to 95.47 years) for women and men respectively. This difference was
statistically significant (t (337) = 3.28, p = 0.001).
Discussion
Our overall survival is somewhat better than 56% 5-year survival reported for oral cancer in
England in 2010. This may be a reflection of the treatment methods. This work supports the
view that aggressive management may improve overall survival.
3Introduction
Oral squamous cell carcinoma (OSCC) is the most common intraoral malignancy and may
have neck node metastases. Even amongst patients with no clinical or radiological evidence
of lymph node metastases preoperatively, 20-30% of all specimens reveal positive nodes in
pathohistological analysis.1,2,3,4 OSCC includes tumours of the anterior two thirds of tongue,
floor of mouth, buccal mucosa, retromolar area, gingivae and palate. Globally oral and
oropharyngeal cancer is the 6th most common cancer and OSCC accounts for the majority of
these.5,6 There has been a significant increase in oral cancer diagnosis in recent decades
which may be attributed to increased exposure to risk factors such as tobacco and alcohol.7
Oral cancer and particularly tongue cancer is also on the increase in young adults under the
age of 45 years.6,8Our unit has advocated radical primary surgery with free tissue transfer
reconstruction where indicated in the management of oral cancer. A selective neck dissection
is performed when depth of tumour invasion exceeds 3 mm. Operations are performed with
intention to cure by resection of in excess of a 0.5 cm margin of normal tissue.  This is  the
practice of several international units. Cure and survival is of primary concern for patients
however  there  are  several  problems  with  basing  outcome  exclusively  on  overall  survival.
Patients are relatively elderly and often have associated co-morbidity associated with their
life style and background. Therefore following oral cancer treatment they can die of other
causes and have life expectancy of less than five years (5-years survival).9The main aims of
this work are to evaluate our service and identify the overall survival of a consecutive series
of  patients  presenting  with  oral  cancer  and  to  relate  survival  to  clinical  and  pathological
factors.
Methods
Data was recorded in an Access 97 database. Clinical data and basic socio-demographic
details were extracted from the database. These were patients treated by the senior authors, in
Leeds General Infirmary and represents more than half of the total number of patients treated
by all teams in the unit within this time frame. Independent groups t-test was used to evaluate
differences between gender and age at diagnosis as well as age at death. Life tables were used
to calculate survival rates at 1, 2, 3, 5 and 10 years’ post-diagnosis. Kaplan-Meier curves
were produced for site, gender, TNM status, and post-operative radiotherapy. The log-rank
4test was used to evaluate differences between factors. Statistical significance was set at
p<0.05. The data were analysed using the software IBM SPSS Statistics version 23.
Results
Clinical features
A total of 921 patients were recorded in the database with a diagnosis of oral squamous cell
carcinoma out of a total of 1958 (43.1%). The most common sites were the tongue (350/921,
38% of cases), followed by floor of mouth (208/921, 22.58%).
The earliest date of diagnosis was 1973. The data were censored at 31 March 2016. The
database comprised 340 women (36.92%) and 581 men (63.08%) (Table 1).
The mean age at diagnosis was 63.59 years (range: 20.68 to 96.07 years). Women were on
average slightly older at diagnosis compared to men: 66.38 years (range: 26.78 to 96.07
years) and 61.96 years (range: 20.68 to 90.75 years), respectively. This difference was
statistically significant (t (919) = 5.08, p<0.0001). A total of 339 deaths were recorded
(34.51%): 117 women (33.7%) and 222 men (65.49%). The mean age at death was 73.37
years (range: 31.38 to 97.51 years) and 68.65 years (range: 33.29 to 95.47 years) for women
and men respectively. This difference was statistically significant (t(337) = 3.28, p = 0.001).
Survival by gender
The mean overall length of survival was 8.11 years (range: 0.0 to 34.08 years). The 1, 3, 5
and 10-year survival rates were as follows: 0.87, 0.80, 0.70 and 0.62, respectively. The mean
survival time (Table 2) was longer for men (20.52 years, 95% confidence intervals (CI):
19.10 to 21.94) compared to women (17.76 years, 95%CI: 16.06 to 19.47) (Figure A). This
was not statistically significant (X2(1) = 1.07, p = 0.30).
Survival by site
There were 5 sites with N>40, namely tongue, floor of mouth, retromolar area (RA), buccal
mucosa (BM) and mandibular alveolus (MA). The longest mean survival (Figure B) was
registered by the latter group of patients at 20.74 years (95%CI 16.13 to 25.34), whereas the
RA group had the lowest mean survival at 15.05 years (95%CI 12.11 to 18.00). There were
no statistically significant differences between the sites (X2(4) = 5.04, p = 0.284).
5Survival by T,N and M status (Table 3)
T-status
The longest mean survival (excluding TX patients) was shown for patients with T1 status
(24.48 years, 95%CI 22.45 to 26.50) compared to a mean survival of 13.03 years (95%CI
11.56 to 14.49) for patients with T4 status (Figure C) which was statistically significant
(X2(4)=39.14, p<0.0001).
N-status
A  similar  pattern  was  also  observed  for  N-status  with  patients  (excluding  NX)  with  no
regional lymph node involvement demonstrating the longest mean survival (21.23 years,
95%CI 19.34 to 23.19) and patients with N3 involvement the shortest (5.52 years, 95%CI
2.54 to 8.50) (Figure D). This was statistically significant (X2(3)=23.74, p<0.0001).
M-status
Finally,  patients with metastatic disease (M1) had shorter survival times than those with no
metastatic disease: 5.94 years (95%CI 2.51 to 9.38) and 20.55 years (95%CI 19.03 to 22.07)
respectively (Figure E). This was also statistically significant (X2(2)=4.55, p=0.005) although
the number of patients with metastatic disease was small (n=11).
Survival by post-operative radiotherapy
The average length of survival for patients who had undergone post-operative radiotherapy
was 17.19 years (95%CI 15.41 to 18.97) compared to 20.50 years (95%CI 18.82 to 22.19) for
those  who  had  only  undergone  surgery  (Figure  F).  This  difference  was  not  statistically
significant (X2(1) = 0.12, p = 0.73).
Discussion
Here we analysed data in our unit from 1973. We were in a position to follow-up patients for
at least 5 years. Our overall survival is somewhat better than data presented before and this
may be a reflection of the treatment.1 The data have been recorded prospectively. A
comprehensive analysis is presented and includes survival by gender, by cancer site, TNM
status, and post-operative radiotherapy. This is a single centre experience and this is a
weakness of this study. Also, another weakness is the fact that these are patients of one of the
teams in the unit and not the total number treated by all surgeons. Gaps in the data collection
are present but in this work we could draw meaningful conclusions. The overall 5-year
6survival for our study population was 70% which is comparable to or better than international
standards.1,9,10,11 The 1,3,5 and 10-year survival rates were as follows: 0.87, 0.80, 0.70 and
0.62. In terms of gender the mean survival for men was longer (20.52 years, 95% confidence
interval (CI):19.10 to 21.94) in comparison to women (17.76 years, 95%CI: 16.06 to 19.47).
This difference was not statistically significant. These results are similar to those by
(Honorato et al, 2015)12 who found no difference in survival outcomes for OSCC between
males and females. In terms of difference between genders, past tobacco use is an
independent prognostic factor for worse survival among males.12The most common sites of
presentation of OSCC with N>40 were tongue, floor of mouth, retromolar area, buccal
mucosa and mandibular alveolus. The longest mean survival was for the mandibular alveolus
group at 20.74 years and the lowest for the retromolar area at 15.05 years. There were no
statistically significant differences between the sites. This is consistent with other reports
highlighting tongue and floor of mouth as the most common sites.10,13 The site of presentation
does not appear to be a significant factor in prognosis, tongue cancer does not appear to have
a worse prognosis, the main prognostic factors affecting survival are the stage and grade of
cancer.13The stage of OSCC had a significant impact on survival in our study. The longest
mean survival was shown for patients with T1 status (24.48 years) compared to a mean
survival of 13.03 years for patients with T4 status. The N-status also showed a significant
difference in survival for N0 and N1 involvement at 21.27 and 16.67 years respectively, in
comparison to N3 status with shortest survival (5.52 years). The clinical nodal stage has been
reported as a significant prognostic factor in survival for OSCC.14The prognosis for patients
treated for OSCC depends mainly on tumour factors, treatment and patient factors. The TNM
classification system relates well to overall survival rate. The prognosis is best for early
detected tumours which are well differentiated with no evidence of regional nodal or distant
metastasis.15 There are a number of histopathological factors which are of important
prognostic importance, these are tumour thickness, positive margins, extracapsular spread of
nodal metastasis.16,17 The current UK National guidelines also advocate that elective neck
treatment should be offered for all oral cancers.17 Recent evidence suggests that selective
elective neck dissection offers improved overall and disease free survival compared with
therapeutic neck dissections for all oral cancers.18 This evidence also advocates use of neck
dissection for smaller tumours less than 4mm thickness. The National Institute for Health and
Care Excellence (NICE) guidelines for T1 and T2 N0 oral cancers suggest that patients be
offered elective neck dissection or sentinel lymph node biopsy instead of elective neck
dissection. This approach avoids the morbidity of neck dissection and may be considered
7unless cervical access is required for free flap reconstruction.19 Although currently advocated
by NICE there are substantial logistical issues nationally which have not been addressed and
robust studies into patient acceptance, survival, morbidity and quality of life are awaited. The
mean length of survival for patients in this study who underwent postoperative radiotherapy
was 17.19 years compared to 20.50 years for those who had surgery only. This difference was
not statistically significant. This may also represent the fact that radiotherapy in our unit is
given to patients with adverse clinical and histopathological features that may include close
margins, significant nodal involvement, extracapsular spread and neurovascular invasion. The
indications for postoperative radiotherapy are not clearly defined for patients in the group
commonly referred to as ‘an intermediate risk group’ in the UK. Although the results for this
patient group have not been presented in this work, in our practice we advocate radiotherapy
more often than not. Radiotherapy as primary treatment is less commonly used in oral cavity
cancers than other head and neck sites.16,20 Our unit advocates the use of surgery and
adjuvant radiotherapy to improve outcomes for locally advanced disease which is operable.
Recent evidence suggests improved survival for locally advanced T3 and T4a OSCCs when
treated with surgery and postoperative radiotherapy compared with chemoradiotherapy.21The
management of oral cancer in our unit is currently to perform primary surgery and adjuvant
therapy where indicated. The current United Kingdom National Multidisciplinary Guidelines
for head and neck cancer advocate surgery as the primary treatment strategy for oral cancers.
Curative surgery involves tumour resection with clinical clearance of 1 cm vital structures
permitting.17 Where close margins of less than 5 mm occur, further treatment with further
resection or adjuvant therapy is considered although robust data suggests no significant
difference between clear margins of 5 mm and 2 mm.22   Following resection, the use of free
tissue transfer where indicated with tailored tissues has lead to improved functional and
cosmetic outcomes.15 The use of vascularised composite flaps allows more aggressive
ablative surgery and restoration of soft tissues and jaw continuity. These reconstructions also
help to withstand post-operative radiotherapy and hence improve survival.23,24
Conclusion
This work is comparable with or better than data from other UK and international units. It is
one of the largest studies involving patients with oral cancer in the UK. This works supports
the view that aggressive primary surgical management may improve overall survival.
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Table 1. Basic clinical features
Site Female Male Total
Overall
%
Tongue 134 216 350 38.00
FOM 65 143 208 22.58
Retromolar area 16 51 67 7.27
Buccal mucosa 27 27 54 5.86
Mandibular alveolus 16 35 51 5.53
Soft palate 12 24 36 3.91
Mandibular gingivae 18 13 31 3.36
Soft and hard palate 9 14 23 2.50
Maxillary alveolus 7 15 22 2.39
Buccal and labial sulcus 7 9 16 1.74
Labial sulcus 3 7 10 1.09
Hard palate 4 4 8 0.87
Lower lip mucosa 2 6 8 0.87
Unclassified 2 4 6 0.65
FOM with mandibular invasion 5 1 6 0.65
Upper & Lower Buccal/Labial Sulcus 4 1 5 0.54
Maxillary gingivae 2 2 4 0.43
Soft palate and maxillary alveolus 3 1 4 0.43
Buccal sulcus 0 2 2 0.22
FOM and mandible 1 1 2 0.22
Buccal mucosa and hard palate 0 1 1 0.11
Buccal mucosa and labial sulcus 1 0 1 0.11
FOM and gingivae 0 1 1 0.11
FOM and tongue 0 1 1 0.11
Labial and buccal mucosa 0 1 1 0.11
Lateral tongue 0 1 1 0.11
Retromolar trigone 1 0 1 0.11
Retromolar trigone, soft palate, FOM 1 0 1 0.11
Total: 340 581 921
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Figure A. Survival by gender
Table 2: Mean survival time
Sex Female Male Total
Mean Min-Max Mean Min-Max Mean Min-Max
Age at diagnosis 66.38
26.78 -
96.07 61.96
20.68 -
90.75 63.59
20.68 -
96.07
Age at death 73.37
31.38 -
97.51 68.65
33.29 -
95.47 70.28
31.38 -
97.51
Survival 8.29
0.025 -
28.38 8.01 0 - 34.08 8.11 0 - 34.08
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Figure B: Survival by site
Figure C. Survival by T-status
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Figure D. Survival by N-status
Figure E. Survival by M-status
15
Table 3. Summary of survival by factors
Female Male Total %
Survival Alive 223 359 582 63.19
Deceased 117 222 339 36.81
Post-operative
Radiotherapy No 278 438 716 77.74
Yes 62 143 205 22.26
T-status T1 117 154 271 29.42
T2 97 186 283 30.73
T3 12 42 54 5.86
T4 85 161 246 26.71
TIS 16 19 35 3.80
TX 2 3 5 0.54
Missing 11 16 27 2.93
N-status N0 235 359 594 64.50
N1 54 111 165 17.92
N2 36 87 123 13.36
N3 5 9 14 1.52
NX 1 1 2 0.22
Missing 9 14 23 2.50
M-status M0 304 530 834 90.55
M1 4 7 11 1.19
MX 22 30 52 5.65
Missing 10 14 24 2.61
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Figure F. Survival by post-operative radiotherapy
